Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis

American Journal of Nephrology

Volumn 42, Issue , 2015, Pages 25-34

  Scialla, Julia J ^a,b   Parekh, Rulan S ^c   Eustace, Joseph A ^d   Astor, Brad C ^e   Plantinga, Laura ^f   Jaar, Bernard G ^g,h   Shafi, Tariq ^g   Coresh, Josef ^g,i   Powe, Neil R ^j   Melamed, Michal L ^k  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY COLLEGE CORK   (Ireland)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f EMORY UNIVERSITY   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Dialysis; End stage renal disease; Epidemiology; Fibroblast growth factor 23; Phosphorus; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; FIBROBLAST GROWTH FACTOR 23; MINERAL; PARATHYROID HORMONE; PHOSPHORUS; 25-HYDROXYVITAMIN D; FIBROBLAST GROWTH FACTOR; VITAMIN D;

ADULT; AFRICAN AMERICAN; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD CHEMISTRY; BLOOD SAMPLING; CALCIUM BLOOD LEVEL; CHEMICAL PARAMETERS; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; END STAGE RENAL DISEASE; FEMALE; HAZARD RATIO; HEMODIALYSIS PATIENT; HOMEOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; RENAL REPLACEMENT THERAPY; RISK FACTOR; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BLOOD; EPIDEMIOLOGY; ETHNOLOGY; HEMODIALYSIS; HEMOSTASIS; KIDNEY FAILURE, CHRONIC; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGED; ALKALINE PHOSPHATASE; CALCIUM; FEMALE; FIBROBLAST GROWTH FACTORS; HEMOSTASIS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; RENAL DIALYSIS; RISK FACTORS; UNITED STATES; VITAMIN D;

EID: 84940668440     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000438999     Document Type: Article

References (50)

1. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
2. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
3. Silver J, Naveh-Many T: FGF-23 and secondary hyperparathyroidism in chronic kidney disease. Nat Rev Nephrol 2013; 9: 641-649.
4. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, et al: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87:E10-E17.
5. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al: FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408.
6. Amann K, Tornig J, Kugel B, Gross M, Tyralla K, El-Shakmak A, et al: Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 2003; 63: 1296-1301.
7. Lam D, Kao W, Sozio S, Meoni L, Shafi T, Jaar B, et al: Interdialytic ionized calcium is associated with a pro-arrhythmic phenotype in incident dialysis patients: the predictors of arrhythmic and cardiovascular risk in ESRD (PACE) study. J Am Soc Nephrol 2011; 22: 487A.
8. Pun PH, Horton JR, Middleton JP: Dialysate calcium concentration and the risk of sudden cardiac arrest in hemodialysis patients. Clin J Am Soc Nephrol 2013; 8: 797-803.
9. Bell NH, Greene A, Epstein S, Oexmann MJ, Shaw S, Shary J: Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest 1985; 76: 470-473.
10. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, et al; HOST Investigators: FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011; 22: 1913-1922.
11. Robinson-Cohen C, Hoofnagle AN, Ix JH, Sachs MC, Tracy RP, Siscovick DS, et al: Racial differences in the association of serum 25-hydroxyvitamin D concentration with coronary heart disease events. JAMA 2013; 310: 179-188.
12. Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, et al: Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70: 351-357.
13. Miskulin DC, Martin AA, Brown R, Fink NE, Coresh J, Powe NR, et al: Predicting 1 year mortality in an outpatient haemodialysis population: a comparison of comorbidity instruments. Nephrol Dial Transplant 2004; 19: 413-420.
14. Athienites NV, Miskulin DC, Fernandez G, Bunnapradist S, Simon G, Landa M, et al: Comorbidity assessment in hemodialysis and peritoneal dialysis using the index of coexistent disease. Semin Dial 2000; 13: 320-326.
15. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, et al: Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004; 291: 451-459.
16. Scialla JJ, Astor BC, Isakova T, Xie H, Appel LJ, Wolf M: Mineral metabolites and CKD progression in African Americans. J Am Soc Nephrol 2013; 24: 125-135.
17. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
18. Kalantar-Zadeh K, Miller JE, Kovesdy CP, Mehrotra R, Lukowsky LR, Streja E, et al: Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patients. J Bone Miner Res 2010; 25: 2724-2734.
19. Wolf M, Betancourt J, Chang Y, Shah A, Teng M, Tamez H, et al: Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol 2008; 19: 1379-1388.
20. Ennis J, Worcester E, Coe F: Contribution of calcium, phosphorus and 25-hydroxyvitamin D to the excessive severity of secondary hyperparathyroidism in African-Americans with CKD. Nephrol Dial Transplant 2012; 27: 2847-2853.
21. Gupta A, Kallenbach LR, Zasuwa G, Divine GW: Race is a major determinant of secondary hyperparathyroidism in uremic patients. J Am Soc Nephrol 2000; 11: 330-334.
22. De Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM: The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol 2002; 13: 2762-2769.
23. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, et al; HOST (Homocysteinemia in Kidney and End Stage Renal Disease) Study Investigators: Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease. Am J Kidney Dis 2012; 60: 567-575.
24. Jovanovich A, Chonchol M, Cheung AK, Kaufman JS, Greene T, Roberts WL, et al: Racial differences in markers of mineral metabolism in advanced chronic kidney disease. Clin J Am Soc Nephrol 2012; 7: 640-647.
25. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; 113:S1-S130.
26. Melamed ML, Michos ED, Post W, Astor B: 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168: 1629-1637.
27. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, et al: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013.
28. Drechsler C, Verduijn M, Pilz S, Dekker FW, Krediet RT, Ritz E, et al: Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2011; 26: 1024-1032.
29. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, et al: Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with allcause and cardiovascular mortality. Arch Intern Med 2008; 168: 1340-1349.
30. Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Jain A, Schreiber MJ Jr, et al: Low 25-hydroxyvitamin D levels and mortality in nondialysis-dependent CKD. Am J Kidney Dis 2011; 58: 536-543.
31. Pilz S, Tomaschitz A, Friedl C, Amrein K, Drechsler C, Ritz E, et al: Vitamin D status and mortality in chronic kidney disease. Nephrol Dial Transplant 2011; 26: 3603-3609.
32. Zittermann A, Iodice S, Pilz S, Grant WB, Bagnardi V, Gandini S: Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. Am J Clin Nutr 2012; 95: 91-100.
33. Kucirka LM, Grams ME, Lessler J, Hall EC, James N, Massie AB, et al: Association of race and age with survival among patients undergoing dialysis. JAMA 2011; 306: 620-626.
34. Foster MC, Coresh J, Fornage M, Astor BC, Grams M, Franceschini N, et al: APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol 2013; 24: 1484-1491.
35. Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, et al: APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 2013; 369: 2183-2196.
36. Grams ME, Chow EK, Segev DL, Coresh J: Lifetime incidence of CKD stages 3-5 in the United States. Am J Kidney Dis 2013; 62: 245-252.
37. Kiberd BA, Clase CM: Cumulative risk for developing end-stage renal disease in the US population. J Am Soc Nephrol 2002; 13: 1635-1644.
38. Crews DC, Sozio SM, Liu Y, Coresh J, Powe NR: Inflammation and the paradox of racial differences in dialysis survival. J Am Soc Nephrol 2011; 22: 2279-2286.
39. Yan G, Norris KC, Yu AJ, Ma JZ, Greene T, Yu W, et al: The relationship of age, race, and ethnicity with survival in dialysis patients. Clin J Am Soc Nephrol 2013; 8: 953-961.
40. Buckalew VM Jr, Freedman BI: Reappraisal of the impact of race on survival in patients on dialysis. Am J Kidney Dis 2010; 55: 1102-1110.
41. Scialla J, Kao WH, Crainiceanu C, Sozio SM, Oberai PC, Shafi T, et al: Biomarkers of vascular calcification and mortality in patients with ESRD. Clin J Am Soc Nephrol 2014; 9: 745-755.
42. Shafi T, Zager PG, Sozio SM, Grams ME, Jaar BG, Christenson RH, et al: Troponin I and NT-proBNP and the association of systolic blood pressure with outcomes in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. Am J Kidney Dis 2014; 64: 443-451.
43. Wassel CL, Pankow JS, Peralta CA, Choudhry S, Seldin MF, Arnett DK: Genetic ancestry is associated with subclinical cardiovascular disease in African-Americans and Hispanics from the Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Genet 2009; 2: 629-636.
44. Bild DE, Detrano R, Peterson D, Guerci A, Liu K, Shahar E, et al: Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2005; 111: 1313-1320.
45. Weinstein RS, Bell NH: Diminished rates of bone formation in normal black adults. N Engl J Med 1988; 319: 1698-1701.
46. Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, et al: Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 2013; 369: 1991-2000.
47. Bhan I, Powe CE, Berg AH, Ankers E, Wenger JB, Karumanchi SA, et al: Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int 2012; 82: 84-89.
48. Cosman F, Morgan DC, Nieves JW, Shen V, Luckey MM, Dempster DW, et al: Resistance to bone resorbing effects of PTH in black women. J Bone Miner Res 1997; 12: 958-966.
49. Levin GP, Robinson-Cohen C, de Boer IH, et al: Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA 2012; 308: 1898-1905.
50. Ito K, Bick AG, Flannick J, Friedman DJ, Genovese G, Parfenov MG, et al: Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. Circ Res 2014; 114: 845-850.